693 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-ZC-FT-413860 May 14, 2019 - Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
Top Stock Reports for Amgen, Altria & Booking Holdings http://www.zacks.com/research-daily/413362/top-stock-reports-for-amgen-altria-booking-holdings?cid=CS-ZC-FT-413362 May 13, 2019 - Top Stock Reports for Amgen, Altria & Booking Holdings
Why Are Investors Passing on Teva Pharmaceutical Industries? https://www.fool.com/investing/2019/05/05/why-are-investors-passing-on-teva-pharmaceutical-i.aspx?source=iedfolrf0000001 May 05, 2019 - Teva's turnaround won't kick into high gear anytime soon.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-ZC-FT-408333 May 03, 2019 - Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates http://www.zacks.com/stock/news/406790/biotech-stock-roundup-biib-vrtx-alxn-q1-earnings-top-other-pipeline-updates?cid=CS-ZC-FT-406790 May 01, 2019 - Key highlights of the past week are earnings releases by most leading biotech entities.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1? http://www.zacks.com/stock/news/406700/can-allergan-agn-beat-earnings-estimates-again-in-q1?cid=CS-ZC-FT-406700 May 01, 2019 - Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4258358-amgen-inc-amgn-ceo-bob-bradway-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 30, 2019 - Amgen Inc. (NASDAQ:AMGN) Q1 2019 Earnings Conference Call April 30, 2019 05:00 PM ET Company Participants Arvind Sood - VP of IR Bob Bradway - Chairman and CEO David Meline - CFO Murdo Gordon - Head o
Amgen Inc (AMGN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/30/amgen-inc-amgn-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 30, 2019 - AMGN earnings call for the period ending March 31, 2019.
Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut http://www.zacks.com/stock/news/406076/lilly-lly-down-despite-q1-earnings-beat-on-sales-view-cut?cid=CS-ZC-FT-406076 Apr 30, 2019 - Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Is a Beat in Store for Cigna (CI) This Earnings Season? http://www.zacks.com/stock/news/405319/is-a-beat-in-store-for-cigna-ci-this-earnings-season?cid=CS-ZC-FT-405319 Apr 29, 2019 - Cigna's (CI) Q1 earnings should benefit from increase in revenues and membership.

Pages: 12345678...70

<<<Page 3>